Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.50 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27153081 | 1.00 | TLR2 (0.50) | TLR2MDM4TP53MDM2KMT2A | |
| SCHEMBL30771499 | 1.00 | TLR2 (0.50) | TLR2MDM4TP53MDM2KMT2A | |
| SCHEMBL30771405 | 1.00 | TLR2 (0.50) | TLR2MDM4TP53MDM2KMT2A | |
| SCHEMBL30771460 | 1.00 | TLR2 (0.50) | TLR2MDM4TP53MDM2KMT2A | |
| SCHEMBL16048758 | 0.94 | TLR2 (0.51) | TLR2MDM4TP53MDM2KMT2A | |
| SCHEMBL16048760 | 0.94 | TLR2 (0.51) | TLR2MDM4TP53MDM2KMT2A | |
| SCHEMBL23447164 | 0.93 | TLR2 (0.52) | TLR2MDM4TP53MDM2 | |
| SCHEMBL20193256 | 0.93 | TLR2 (0.47) | TLR2MDM4TP53MDM2 | |
| SCHEMBL20448250 | 0.92 | TLR2 (0.51) | TLR2MDM4TP53MDM2KMT2A | |
| SCHEMBL31267179 | 0.92 | TLR2 (0.51) | TLR2MDM4TP53MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735048-A1 | BIOACTIVE CONJUGATES, PREPARATION METHOD AND USE THEREOF | Beone Medicines I GmbH (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-20260115304-A1 | BIOACTIVE CONJUGATES, PREPARATION METHOD AND USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2026-04-30 | — | — | US | disclosed |
| WO-2025002368-A1 | BIOACTIVE CONJUGATES, PREPARATION METHOD AND USE THEREOF | BEIGENE, LTD. (GB) | 2025-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115304-A1 | BIOACTIVE CONJUGATES, PREPARATION METHOD AND USE THEREOF | GUSB, PSMA6, CD44 | TLR2 2200/4885MDM4 3780/4885TP53 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.